The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

• Published in: Leukemia Vol. 28; no. 10; pp. 1953 - 1959
• Main Authors: Lazenby, M, Gilkes, A F, Marrin, C, Evans, A, Hills, R K, Burnett, A K
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.10.2014
• Subjects: Acute myeloid leukemia; Aged; Care and treatment; Drug dosages; Female; fms-Like Tyrosine Kinase 3 - genetics; Gene mutations; Genetic aspects; Genotype; Genotypes; Hematology; Humans; Identification and classification; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Male; Medical prognosis; Medical research; Middle Aged; Mutation; Nuclear Proteins - genetics; Patients; Prognosis; Recurrence; Remission; Remission (Medicine); Remission Induction; Risk; Subgroups; Survival; Treatment Outcome; United Kingdom; United Kingdom > UK
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/leu.2014.90

Although the prognostic impact of mutations of FLT3 and NPM1 have been extensively studied in younger patients with acute myeloid leukaemia, less is known in older patients whether treated intensively or non-intensively, or in the context of existing prognostic scores. In 1312 patients 16 and 21%, respectively had an FLT3 and NPM1 mutation. An FLT3 mutation did not affect remission rate in intensively or non-intensively treated patients but was associated with an inferior survival. All patients with an NPM1c mutation had a significantly higher remission rate irrespective of treatment approach but survival was not improved, overall, or in any genotype except as in younger patients, in the FLT3 WT NPM1c mutant subgroup. When incorporated into an established multi-parameter prognostic risk score, the molecular information provided additional prognostic definition in 11% of patients.